ArticleActa dermato-venereologica2025
New-onset Autoimmune Diseases in Patients with Prurigo Nodularis: A Global-federated Retrospective Cohort Study.
Article in Acta dermato-venereologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prurigo nodularis (PN) has been associated with autoimmune diseases, though longitudinal data are limited. This study investigates the risk of autoimmune disease development in PN patients using a global electronic health record database. This retrospective cohort study analysed data from the Global Collaborative Network within the TriNetX research network. Adults (≥ 18 years) with PN were compared with propensity score-matched controls without PN. Matching considered age, sex, comorbidities, race, and socioeconomic status. Patients with prior autoimmune diseases or cancers were excluded. Incident autoimmune diseases, including systemic lupus erythematosus (SLE), Sjögren's syndrome, psoriasis, ankylosing spondylitis (AS), rheumatoid arthritis (RA), Crohn's disease (CD), and ulcerative colitis (UC), were evaluated using hazard ratios (HR). Among 17,963 PN patients and the same amount of matched pairs, PN patients had higher risks for SLE (HR: 2.16, 95% CI: 1.44-3.24), Sjögren's syndrome (HR: 1.86, 95% CI: 1.33-2.59), and psoriasis (HR: 3.20, 95% CI: 2.58-3.97). Stratified analysis revealed that female PN patients had higher risks for SLE and Sjögren's syndrome, while psoriasis risk was elevated in both sexes, especially in males. Risks for AS, RA, CD, and UC were not significant. Sensitivity analyses validated these findings. In conclusion, PN is linked to increased risks for SLE, Sjögren's syndrome, and psoriasis, highlighting the need for proactive screening and management of autoimmune diseases in PN patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.